- Advertisement -
More than two years after losing 87 per cent of its value in a single day when a clinical study for its drug pezadeftide in treating mould infections came up as “inconclusive”, biotech Hexima (ASX: HXL) is using its listed position to pivot into an entirely new field of next-gen autonomous…
